Back

Find the FamiCord brand in your country

Free guide

Smart Cells free guide

Download

Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

  • Blood cancers such as leukaemia and lymphoma
  • Inherited genetic disorders including thalassemia and sickle cell disease
  • Neurological conditions such as cerebral palsy and brain injury
  • Immune deficiencies and metabolic disorders
  • Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

  • Cerebral Palsy
  • Thalassemia
  • Leukaemia
  • HSV Encephalitis
  • Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

  • Families gain access to 1,000,000+ stored cord blood units across the network
  • Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
  • FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

FamiCord Group releases

Patients

7800+

Expand table
No. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
201 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Canada 69
202 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 66
203 Apheresis Allogeneic Fanconi Anemia Hematology 2026 Standard Therapy Germany 4
204 Apheresis Allogeneic Leukemia T-PLL Hematology 2026 Standard Therapy Norway 64
205 Apheresis Allogeneic T-cell NHL Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 46
206 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 60
207 Apheresis Allogeneic MM, Myeloma Multiplex Hematology 2026 Standard Therapy Poland 48
208 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Norway 29
209 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 27
210 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Austria 34
211 Apheresis Allogeneic Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS) Hematology 2026 Standard Therapy Poland 55
212 Apheresis Allogeneic Thalassemia Major Hematology 2026 Standard Therapy Turkey 11
213 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Norway 59
214 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 75
215 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Hungary 62
216 Apheresis Allogeneic 2nd Myelodysplastic Syndrome Hematology 2026 Standard Therapy Netherlands 67
217 Apheresis Allogeneic Acute Myelomonocytic Leukemia (AMML) Hematology 2026 Standard Therapy Ukraine 44
218 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Portugal 59
219 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Germany 54
220 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 67
221 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Spain 47
222 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Hungary 42
223 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Hungary 67
224 Apheresis Allogeneic Prolymphocytic Leukemia Hematology 2026 Standard Therapy USA 66
225 Apheresis Allogeneic Other Myelofibrosis/Myelosclerosis Hematology 2026 Standard Therapy USA 59
226 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 52
227 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 57
228 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 56
229 Apheresis Allogeneic Chronic Myelomonocytic Leukemia (CMML) Hematology 2026 Standard Therapy Germany 56
230 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Ukraine 37
231 Apheresis Allogeneic Sickle Cell Anemia Hematology 2026 Standard Therapy Germany 10
232 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 71
233 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Canada 69
234 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 51
235 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 63
236 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 65
237 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Sweden 68
238 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Czechia 67
239 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 63
240 Apheresis Allogeneic Chronic Lymphocytic Leukemia Hematology 2026 Standard Therapy Australia 57
241 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 51
242 Apheresis Allogeneic B-Cell Acute Lymphoblastic Leukemia (B-ALL) Hematology 2026 Standard Therapy Poland 46
243 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 59
244 Apheresis Allogeneic Primary Myelofibrosis (PMF) Hematology 2026 Standard Therapy Poland 59
245 Apheresis Autologous T-cell Lymphoblastic Lymphoma Hematology 2026 Standard Therapy Germany 40
246 Apheresis Autologous Anaplastic Large-Cell Lymphoma Hematology 2026 Standard Therapy Germany 68
247 Apheresis Autologous Central Nervous System Lymphoma Hematology 2026 Standard Therapy Germany 51
248 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 64
249 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 58
250 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 63
251 Apheresis Autologous T-Cell Lymphoma Hematology 2026 Standard Therapy Germany 68
252 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 68
253 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 65
254 Apheresis Allogeneic Chronic Myeloid Leukemia Hematology 2026 Standard Therapy United Kingdom 55
255 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Poland 65
256 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Austria 43
257 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 60
258 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Poland 58
259 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Spain 66
260 Apheresis Allogeneic Myelodysplastic Syndrome IB2 Hematology 2026 Standard Therapy Germany 59
261 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 63
262 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Israel 74
263 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 67
264 Apheresis Allogeneic Serum Amyloid A (SAA) Hematology 2026 Standard Therapy United Kingdom 11
265 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 54
266 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy India 52
267 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy India 45
268 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 62
269 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Netherlands 47
270 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 58
271 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Lithuania 63
272 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 56
273 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 72
274 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 30
275 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 69
276 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 70
277 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Ireland 73
278 Apheresis Allogeneic Other Leukemia, Specify, Chronic Neutrophilic Leukemia Hematology 2026 Standard Therapy USA 56
279 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 60
280 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Spain 64
281 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 66
282 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 33
283 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Switzerland 69
284 Apheresis Allogeneic CML Blast Crisis Hematology 2026 Standard Therapy Poland 38
285 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy India 34
286 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Bulgaria 49
287 Apheresis Allogeneic Hodgkin lymphoma Hematology 2026 Standard Therapy Russian Federation 37
288 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 65
289 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 24
290 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 58
291 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 69
292 Apheresis Allogeneic Chronic Lymphocytic Leukemia Hematology 2026 Standard Therapy Poland 63
293 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Belgium 64
294 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Argentine 52
295 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 71
296 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 55
297 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 75
298 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 69
299 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Poland 12
300 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 71
Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

Icon

100% infusion success rate

For samples released for transplant.

Icon

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

Icon

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

24

Expand table
Sample release date Medical condition Recipient relationship Age of the recipient Unit volume Medical center Country
2005.11 Thalassemia Allogeneic (Sibling) 4 Years 144ml Mount Vernon Hospital Singapore
2005.11 Leukaemia Allogeneic (Sibling) Restricted Restricted Stem Cells and Immunology Department, Birmingham UK
2007.02 Thalassemia Allogeneic (Sibling) 7 Years 76ml Kinderlink der Tu Munchen Germany
2009.08 Cerebral Palsy Autologous (Self) 3 Years 51ml Duke University, North Carolina USA
2010.01 Cerebral Palsy Autologous (Self) 3 Years 81ml Duke University, North Carolina USA
2013.10 Thalassemia Allogeneic (Sibling) 5 Years 58ml Catherine Lewis Centre, Hammersmith UK
2014.01 Leukaemia Allogeneic (Sibling) 4 Years 71ml Medizinische Hochschule, Hanover Germany
2014.05 Cerebral Palsy Autologous (Self) 1 year 68ml Duke University, North Carolina USA
2014.06 HSV Encephalitis & NMDA Receptor Antibody Virus Autologous (Self) 2 Years 57ml Duke University, North Carolina USA
2014.08 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 3 Months 39ml Duke University, North Carolina USA
2015.02 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 6 Months 53ml Duke University, North Carolina USA
2015.03 Severe Combined Immune Deficiency Autologous (Self) 3 Months 74ml Duke University, North Carolina USA
2015.03 Sickle Cell Disease Allogeneic (Sibling) 2 .5 Years 57ml BLK Hospital, New Delhi India
2015.11 Thalassemia Allogeneic (Sibling) 12 Years 87ml Children’s Hospital of Pittsburgh of UPMC USA
2016.03 Cerebral Palsy Allogeneic (Sibling) 6 Years 101ml Duke University, North Carolina USA
2017.04 Lymphoblastic Leukaemia (^1) N/A (Identical twin girls) Restricted 125ml Bambin Gesu Childrens’ Hospital, Rome Italy
2017.06 Cerebral Palsy Autologous (Self) 7 Years 82ml Duke University, North Carolina USA
2017.06 Cerebral Palsy Autologous (Self) 3.4 Years 132ml Duke University, North Carolina USA
2018.03 Autism Autologous (Self) 5.4 Years 73ml Duke University, North Carolina USA
2018.03 Cerebral Palsy Autologous (Self) 3.4 years 132ml Duke University, North Carolina USA
2019.06 Cerebral Palsy Allogeneic (Sibling) 3 Years 104ml Duke University, North Carolina USA
2022.02 Cerebral Palsy Allogeneic (Sibling) 11 Years 185ml Duke University, North Carolina USA
2023.08 Cerebral Palsy Allogeneic (Sibling) 3 Years 46ml Duke University, North Carolina USA
2024.01 Thalassaemia Allogeneic (Sibling) 8 Years 45ml Cincinnati Children’s Hospital Medical Center USA
Expand table
Icon

Ready to get started or need more information?